GI Innovation Inc. Logo

GI Innovation Inc.

Develops fusion protein biologics for oncology, allergic, and metabolic diseases.

358570 | KO

Overview

Corporate Details

ISIN(s):
KR7358570000
LEI:
Country:
South Korea
Address:
서울특별시 송파구 송파대로 167, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

GI Innovation Inc. is a biopharmaceutical company engaged in the research and development of next-generation immunotherapies. The company utilizes its proprietary GI-SMART™ platform to create innovative fusion protein-based biologics. Its development pipeline targets diseases with high unmet medical needs, focusing on therapeutic areas such as immuno-oncology (GI-101, GI-10N), allergic and fibrotic diseases (GI-301, GI-30N), and metabolic diseases (GI-20N). Operating under a "Science, Strategy, Speed" philosophy, GI Innovation advances its drug candidates through well-structured translational research and strategic collaborations with global pharmaceutical companies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (건강한 성인 및 암 생존자를 대상으로 한 GI102 요법의 노화 관련 생…
Korean 8.2 KB
2025-09-05 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획변경승인신청) (GI101 단일 요법 또는 펨브롤리주맙 또는 렌바티닙 병용 요법의 안…
Korean 13.0 KB
2025-09-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-09-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-09-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-09-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 957.2 KB
2025-08-29 00:00
Share Issue/Capital Change
전환주식의전환청구권행사 (전환우선주)
Korean 15.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-08-05 00:00
Share Issue/Capital Change
주요사항보고서(전환사채매수선택권행사자지정)
Korean 23.8 KB
2025-07-10 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.5 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-06-26 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 604.9 KB
2025-06-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-06-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB

Automate Your Workflow. Get a real-time feed of all GI Innovation Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GI Innovation Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GI Innovation Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.